Vir Biotechnology, Inc. (VIR)
After hours:
| Previous close | 8.04 |
| Open | 7.99 |
| Bid | 7.62 x 300 |
| Ask | 7.65 x 200 |
| Day's range | 7.61 - 8.00 |
| 52-week range | 7.61 - 27.48 |
| Volume | |
| Avg. volume | 1,054,298 |
| Market cap | 1.036B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
SAN FRANCISCO, April 18, 2024--Vir Biotechnology, Inc. ("Vir" or "the Company", Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the "Board") at its upcoming annual meeting of stockholders on May 29, 2024 (the "Annual Meeting"). If elected, each of Drs. Bischofberger and Farid will join the Board on such date.
- Business Wire
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
SAN FRANCISCO, April 11, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024.
- Business Wire
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
SAN FRANCISCO, March 05, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated. This includes over 60 participants in two additional cohorts – one evaluating tobevibart given every 2 weeks and the other evaluating the
